Mydecine Innovations Group Inc (OTCMKTS:MYCOF) Strengthens Scientific Advisory Board

Mydecine Innovations Group Inc (OTCMKTS:MYCOF) added two advisors to its scientific advisory committee. They will provide support for corporate strategy and scientific expertise because Mydecine begins its research and development program in Denver, Colorado-based Innovation Center.

Reviews specific proposals

The scientific advisory board will review and supervise the protocols besides offering technical expertise.

The research fellow – Mr. Vince Polito, will engage in understanding the sense of agency, self-representation, self-monitoring of the changes, and changes in consciousness, and belief formation. His previous stints include an investigator at ARCC (Australian Research Council Centre) of Excellence in cognition.

Long term effects of microdosing

Polito conducted a study on psychedelics microdosing in 2019. Another scientific advisor to join the committee is Madrid, Spain based Psychopharmacology expert – Anton Gomez-Escolar. He got expertise in psychopharmacology, neurobiology, drug safety, nootropics, psychedelics, and clinical studies.

Director and CSO, Rob Roscow said the scientific advisory committee is responsible for providing a multi-disciplinary, expert, independent, strategic advice on various scientific programs, upcoming trends in psychedelics, and emerging issues in health sciences Mydecine.

Signs a deal to takeover Digital Telehealth Platform

Mydecine entered an agreement to take over a 100% stake in the Digital Telehealth platform (DTP) of Mindleap Health Inc. The DTP of Mindleap focuses on the upcoming psychedelics sector. As per the terms of the deal, Mydecine will issue 6.36 million common shares to Mindleap. The company will also provide working capital of CAD 500,000 on closing the transaction to Mindleap. It will also pay an additional sum of CAD 500,000 to Mindleap by September 1, 2020.

Mydecine Group focuses on mental health. According to the estimates of WHO, over 450 million people worldwide are suffering from mental health disorders.

The US accounts for a majority of the population suffering from mental health problems. Director and CEO of Mydecine, Josh Bartch said the takeover helps to bring highly talented professionals with expertise in science, mental health, technology to its fold. A highly scalable platform improves returns of investment because of advances of Mindleap in upcoming and fastest growing psychedelic medicine.